万邦德在研阿尔茨海默症治疗创新药完成100例受试者入组

Core Viewpoint - Wanbangde announced the completion of enrollment of 100 subjects for the Phase II/III pivotal registration clinical trial of its Class 2 new drug, Huperzine A controlled-release tablets, for the treatment of mild to moderate Alzheimer's disease [1] Group 1: Drug Development - Huperzine A is a cholinesterase inhibitor aimed at improving cognitive function [1] - Preclinical studies have shown potential in delaying the progression of Alzheimer's disease, with broad benefits including reduction of beta-amyloid protein, anti-inflammatory effects, antioxidant stress response, and neuroprotection [1] - The drug is expected to become a broad-spectrum treatment for Alzheimer's disease dementia [1]